Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation Industry Key Trends, Size, Growth, Shares and Forecast Research Report
Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the management of recurrent and later-stage disease is largely reliant on cytotoxic chemotherapy regimens.
View full press release